A population-based study comparing biosimilar versus originator erythropoiesis-stimulating agent consumption in 6,117 patients with renal anaemia

European Journal of Clinical Pharmacology

Volumn 69, Issue 4, 2013, Pages 929-936

  Hörbrand, Franziska ^a   Bramlage, Peter ^b   Fischaleck, Johann ^a   Hasford, Joerg ^c   Brunkhorst, Reinhard ^d  

^a Kassenärztliche Vereinigung Bayerns ^*  (Germany)

^b Institut fur Pharmakologie und Praventive Medizin   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d Klinikum Hannover Oststadt   (Germany)

Author keywords

Biosimilar; Cohort study; Darbepoetin alfa; Epoetin; Erythropoietin; M PEG erythropoietin beta; Originator; Therapeutic equivalence

Indexed keywords

ANTIANEMIC AGENT; BIOSIMILAR AGENT; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; HEXAL; LONG ACTING DRUG; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; SHORT ACTING DRUG; UNCLASSIFIED DRUG;

AMBULATORY CARE; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; DATA BASE; DEFINED DAILY DOSE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG USE; HEMODIALYSIS; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; PHARMACOLOGICAL PARAMETERS; PRESCRIPTION; PRIORITY JOURNAL; RENAL ANEMIA;

AGED; ANEMIA; BIOSIMILAR PHARMACEUTICALS; COHORT STUDIES; DATABASES, FACTUAL; DRUG UTILIZATION; ERYTHROPOIETIN; FEMALE; GERMANY; HEMATINICS; HUMANS; MALE; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; SEVERITY OF ILLNESS INDEX;

EID: 84876736657     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1412-5     Document Type: Article

References (26)

1. Jelkmann W (2007) Recombinant EPO production-points the nephrologist should know. Nephrol Dial Transplant 22(10):2749-2753
2. Macdougall IC (2008) Novel erythropoiesis-stimulating agents: a new era in anemia management. Clin J Am Soc Nephrol 3(1):200-207
3. Jelkmann W (2009) Efficacy of recombinant erythropoietins: is there unity of international units? Nephrol Dial Transplant 24(5):1366-1368
4. Brinks V, Hawe A, Basmeleh AH, Joachin-Rodriguez L, Haselberg R, Somsen GW, Jiskoot W, Schellekens H (2011) Quality of original and biosimilar epoetin products. Pharm Res 28(2):386-393
5. Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR et al (1989) Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 111(12):992-1000
6. Goldsmith D, Gesualdo L (2012) Biosimilar epoetins in nephrology - where are we now? Eur Nephrol 6:21-24
7. Covic A, Cannata-Andia J, Cancarini G, Coppo R, Frazao JM, Goldsmith D, Ronco P, Spasovski GB, Stenvinkel P, Utas C, Wiecek A, Zoccali C, London G (2008) Biosimilars and biopharmaceuticals: what the nephrologists need to know - a position paper by the ERA-EDTA Council. Nephrol Dial Transplant 23(12):3731-3737
8. Schellekens H (2004) Biosimilar epoetins: how similar are they? Eur J Hosp Pharm 3:43-47
9. Schöffski O, Müller H-J, Kostev K, Claus D (2011) Consumption of eroythropoiesis-stimulating agents. Nieren- und Hochdruckkrankheiten 40(2):84-90
10. EMA (2010) Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant erythropoietins (Revision). Document: EMEA/CHMP/BMWP/301636/2008. Available at: ema.europa.eu. Accessed 15 Feb 2011
11. Teng L, Xin HW, Blix HS, Tsutani K (2012) Review of the use of defined daily dose concept in drug utilisation research in China. Pharmacoepidemiol Drug Saf. doi: 10.1002/pds.3240
12. Horl WH, Locatelli F, Haag-Weber M, Ode M, Roth K (2012) Prospective multicenter study of HX575 (biosimilar epoetin-I+/-) in patients with chronic kidney disease applying a target hemoglobin of 10-12 g/dl. Clin Nephrol 78(1):24-32
13. WIdO (2010) Anatomisch-therapeutisch chemische Klassifikation mit Tagesdosen - amtliche deutsche Fassung. Accessed: 15 Feb 2011
14. Sorgel F, Thyroff-Friesinger U, Vetter A, Vens-Cappell B, Kinzig M (2009) Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple intravenous administrations: an open-label randomised controlled trial. BMC Clin Pharmacol 9:10
15. Sorgel F, Thyroff-Friesinger U, Vetter A, Vens-Cappell B, Kinzig M (2009) Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple subcutaneous administrations. Pharmacology 83(2):122-130
16. Haag-Weber M, Vetter A, Thyroff-Friesinger U (2009) Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis. Clin Nephrol 72(5):380-390
17. Krivoshiev S, Todorov VV, Manitius J, Czekalski S, Scigalla P, Koytchev R (2008) Comparison of the therapeutic effects of epoetin zeta and epoetin alpha in the correction of renal anaemia. Curr Med Res Opin 24(5):1407-1415
18. Krivoshiev S, Wizemann V, Czekalski S, Schiller A, Pljesa S, Wolf-Pflugmann M, Siebert-Weigel M, Koytchev R, Bronn A (2010) Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia. Adv Ther 27(2):105-117
19. Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R (2008) Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment. Curr Med Res Opin 24(3):625-637
20. Wiecek A, Ahmed I, Scigalla P, Koytchev R (2010) Switching epoetin alfa and epoetin zeta in patients with renal anemia on dialysis: Posthoc analysis. Adv Ther 27(12):941-952
21. Abu-Alfa AK, Sloan L, Charytan C, Sekkarie M, Scarlata D, Globe D, Audhya P (2008) The association of darbepoetin alfa with hemoglobin and health-related quality of life in patients with chronic kidney disease not receiving dialysis. Curr Med Res Opin 24(4):1091-1100
22. Agarwal A, Silver MR, Walczyk M, Liu W, Audhya P (2007) Once-monthly darbepoetin alfa for maintaining hemoglobin levels in older patients with chronic kidney disease. J Am Med Dir Assoc 8(2):83-90
23. Biggar P, Ketteler M, Hennemann H, Domling R (2008) Switch of ESA therapy from darbepoetin-alpha to epoetin-beta in hemodialysis patients: a single-center experience. Clin Nephrol 69(3):185-192
24. Bock HA, Hirt-Minkowski P, Brunisholz M, Keusch G, Rey S, von Albertini B (2008) Darbepoetin alpha in lower-than-equimolar doses maintains haemoglobin levels in stable haemodialysis patients converting from epoetin alpha/beta. Nephrol Dial Transplant 23(1):301-308
25. Brunkhorst R, Bommer J, Braun J, Haag-Weber M, Gill C, Wagner J, Wagener T (2004) Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients. Nephrol Dial Transplant 19(5):1224-1230
26. Locatelli F, Canaud B, Giacardy F, Martin-Malo A, Baker N, Wilson J (2003) Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo). Nephrol Dial Transplant 18(2):362-369